{"transactions":[{"id":2470605,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":132333,"kind":"person","name":"BRISTOW MICHAEL R","position":1,"cik":"0001266125","reported_name":"BRISTOW MICHAEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres. & Chief Executive Offic"}}],"security":"Stock Option (right to buy)","published_at":"2021-12-16T21:31:13.000Z","date":"2021-12-14","kind":"grant","acquired":true,"shares":95000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan (the Plan), vesting in 36 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time.  In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested."}],"balance_after":95000,"derivative":{"exercise_price":2.29,"expiration_date":"2031-12-14","underlying":"Common Stock","underlying_shares":95000},"source":{"system":"sec-edgar","filing":"0001209191-21-069960","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919121069960/doc4.xml","form_type":"4"}},{"id":2933611,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":132333,"kind":"person","name":"BRISTOW MICHAEL R","position":1,"cik":"0001266125","reported_name":"BRISTOW MICHAEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres. & Chief Executive Offic"}}],"security":"Stock Option (right to buy)","published_at":"2020-12-23T21:15:08.000Z","date":"2020-12-21","kind":"grant","acquired":true,"shares":190000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Grant to the Reporting Person of a stock option under the 2020 Equity Incentive Plan (the Plan), vesting in 48 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time.  In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested."}],"balance_after":190000,"derivative":{"exercise_price":4.27,"expiration_date":"2030-12-21","underlying":"Common Stock","underlying_shares":190000},"source":{"system":"sec-edgar","filing":"0001209191-20-065002","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919120065002/doc4.xml","form_type":"4"}},{"id":4359135,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":132333,"kind":"person","name":"BRISTOW MICHAEL R","position":1,"cik":"0001266125","reported_name":"BRISTOW MICHAEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres. & Chief Executive Offic"}}],"security":"Common Stock","published_at":"2017-04-05T20:14:02.000Z","date":"2017-04-04","kind":"sale","acquired":false,"shares":720,"price":2.41,"value":1735.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units (\"RSUs\") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the \"Plan\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) remaining 2,025 previously reported shares issued as RSUs under the Plan that vest on 2/27/18, and (ii) remaining 2,291 previously reported shares issued as RSUs under the Plan that vest on 4/2/18, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 36,839 previously reported shares of common stock held directly."}],"balance_after":41155,"source":{"system":"sec-edgar","filing":"0001209191-17-025617","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919117025617/doc4.xml","form_type":"4"}},{"id":4415398,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":132333,"kind":"person","name":"BRISTOW MICHAEL R","position":1,"cik":"0001266125","reported_name":"BRISTOW MICHAEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres. & Chief Executive Offic"}}],"security":"Stock Option (right to buy)","published_at":"2017-03-01T22:10:37.000Z","date":"2017-02-27","kind":"grant","acquired":true,"shares":41600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant to the Reporting Person of a stock option under the Plan, 50% vesting upon achievement of certain pre-specified corporate milestone related to the outcome of the interim data analysis by that trial's Data and Safety Monitoring Board, and if the milestone is achieved, the remainder of the grant will vest on March 31, 2018, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time.  If the corporate milestone is not achieved, the Option will be cancelled.\nIn the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested."}],"balance_after":41600,"derivative":{"exercise_price":2.6,"expiration_date":"2027-02-26","underlying":"Common Stock","underlying_shares":41600},"source":{"system":"sec-edgar","filing":"0001209191-17-015978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919117015978/doc4.xml","form_type":"4"}},{"id":4415397,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":132333,"kind":"person","name":"BRISTOW MICHAEL R","position":1,"cik":"0001266125","reported_name":"BRISTOW MICHAEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres. & Chief Executive Offic"}}],"security":"Common Stock","published_at":"2017-03-01T22:10:37.000Z","date":"2017-02-28","kind":"sale","acquired":false,"shares":763,"price":2.61,"value":1991.43,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units (\"RSUs\") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the \"Plan\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes (i) remaining 2,025 previously reported shares issued as RSUs under the Plan that vest on 2/27/18, and (ii) 4,581 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning 4/2/17, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 35,269 previously reported shares of common stock held directly."}],"balance_after":41875,"source":{"system":"sec-edgar","filing":"0001209191-17-015978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919117015978/doc4.xml","form_type":"4"}},{"id":4437464,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":132333,"kind":"person","name":"BRISTOW MICHAEL R","position":1,"cik":"0001266125","reported_name":"BRISTOW MICHAEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres. & Chief Executive Offic"}}],"security":"Stock Option (right to buy)","published_at":"2017-02-21T21:49:15.000Z","date":"2017-02-16","kind":"grant","acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Grant to the Reporting Person of a stock option under the Plan, vesting in 36 equal monthly installments from the date of grant, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time.  In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested."}],"balance_after":42000,"derivative":{"exercise_price":2.5,"expiration_date":"2027-02-15","underlying":"Common Stock","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001209191-17-012757","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919117012757/doc4.xml","form_type":"4"}},{"id":4598325,"issuer":{"id":3781,"kind":"organization","name":"Oruka Therapeutics, Inc.","symbol":"ORKA"},"owners":[{"id":132333,"kind":"person","name":"BRISTOW MICHAEL R","position":1,"cik":"0001266125","reported_name":"BRISTOW MICHAEL R","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Pres. & Chief Executive Offic"}}],"security":"Common Stock","published_at":"2016-09-21T20:09:20.000Z","date":"2016-09-20","kind":"sale","acquired":false,"shares":1972,"price":2.89,"value":5699.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person with respect to the vesting of previously reported Restricted Stock Units (\"RSUs\") granted to the Reporting Person under the Issuer's 2013 Amended and Restated Equity Incentive Plan (the \"Plan\")"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $2.88 to $2.89. Upon request of the SEC staff, ARCA biopharma, Inc. (the \"Company\") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes (i) remaining 4,050 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning on 2/27/17, and (ii) 4,581 previously reported shares issued as RSUs under the Plan that vest in two equal annual installments beginning 4/2/17, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 34,007 previously reported shares of common stock held directly."}],"balance_after":42638,"source":{"system":"sec-edgar","filing":"0001209191-16-142261","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/907654/000120919116142261/doc4.xml","form_type":"4"}}]}